Newsfeeds - Spark Newswire

1 minute read

Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate

Today, 12:58 PM

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein for muco-obstructive lung diseases,…

PIRS

2 minute read

Earnings

Pieris Pharmaceuticals’s Return On Capital Employed Insights

By Benzinga Insights

Today, 12:58 PM

Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ:PIRS) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter.

PIRS

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

By Benzinga Insights

Today, 12:58 PM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

2 minute read

Earnings

Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 12:58 PM

According to Benzinga Pro data, during Q1, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $10.99 million. Earnings were up 46.49%, but Pieris Pharmaceuticals still reported an overall loss of $5.10 million.

PIRS

12 minute read

Earnings Scheduled For May 11, 2022

By Benzinga Insights

Today, 12:58 PM

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

ACOR

2 minute read

Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group?

By Henry Khederian

Today, 12:58 PM

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

BIDU

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 12:58 PM

ALDX

1 minute read

Pieris Pharmaceuticals Q3 EPS $(0.24), Inline, Sales $4.06M Miss $5.32M Estimate

By Benzinga Newsdesk

Today, 12:58 PM

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 7.69 percent increase over losses of $(0.26) per share from the same period last

PIRS

19 minute read

Earnings Scheduled For November 2, 2021

By Benzinga Insights

Today, 12:58 PM

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

1 minute read

Earnings

Preview: Pieris Pharmaceuticals’s Earnings

By Benzinga Insights

Today, 12:58 PM

Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate that Pieris Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-0.24

PIRS